Literature DB >> 17990057

Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

A Caroli1, C Testa, C Geroldi, F Nobili, L R Barnden, U P Guerra, M Bonetti, G B Frisoni.   

Abstract

OBJECTIVE: Aim of this study was to find cerebral perfusion correlates of conversion to dementia in patients with amnestic MCI.
METHODS: 17 healthy subjects (age = 69 +/- 3, 9 females), and 23 amnestic MCI patients (age = 70 +/- 6, 10 females) underwent brain MR scan and (99m)Tc ECD SPECT. Conversion to AD was ascertained on average 19 +/- 10 months after baseline: 9 had converted (age = 69 +/- 3, 4 females), and 14 had not (age = 71 +/- 8, 6 females). We processed SPECT images with SPM2 following an optimized protocol and performed a voxel-based statistical analysis comparing amnestic MCI patients converted to AD and non-converted to dementia vs controls. We assessed the effect of gray matter atrophy on the above results with SPM2 using an optimized Voxel-Based Morphometry (VBM) protocol. We compared significant hypoperfusion with significant atrophy on a voxel-byvoxel basis.
RESULTS: In comparison with normal controls, amnestic MCI patients who converted to AD showed hypoperfusion in the right parahippocampal gyrus and left inferior temporal and fusiform gyri,whereas those who did not convert showed hypoperfusion in the retrosplenial cortex, precuneus and occipital gyri, mainly on the left side. We found no overlap between significant atrophy and significant hypoperfusion regions.
CONCLUSIONS: Parahippocampal and inferior temporal hypoperfusion in amnestic MCI patients appears as a correlate of conversion to AD; hypoperfusion in the retrosplenial cortex is involved in memory impairment but does not seem the key prognostic indicator of conversion to dementia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17990057     DOI: 10.1007/s00415-007-0631-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  47 in total

1.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

2.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Functional connectivity with the hippocampus during successful memory formation.

Authors:  Charan Ranganath; Aaron Heller; Michael X Cohen; Craig J Brozinsky; Jesse Rissman
Journal:  Hippocampus       Date:  2005       Impact factor: 3.899

4.  Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD.

Authors:  B Borroni; D Anchisi; B Paghera; B Vicini; N Kerrouche; V Garibotto; A Terzi; L A Vignolo; M Di Luca; R Giubbini; A Padovani; D Perani
Journal:  Neurobiol Aging       Date:  2005-03-24       Impact factor: 4.673

5.  Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

Authors:  Shiming Ye; Yadong Huang; Karin Müllendorff; Liming Dong; Gretchen Giedt; Elaine C Meng; Fred E Cohen; Irwin D Kuntz; Karl H Weisgraber; Robert W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Raven's coloured progressive matrices: normative values on 305 adult normal controls.

Authors:  A Basso; E Capitani; M Laiacona
Journal:  Funct Neurol       Date:  1987 Apr-Jun

7.  Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment.

Authors:  Anna Caroli; Cristina Testa; Cristina Geroldi; Flavio Nobili; Ugo P Guerra; Matteo Bonetti; Giovanni B Frisoni
Journal:  J Neurol       Date:  2007-03-20       Impact factor: 4.849

8.  Antemortem diagnosis of frontotemporal lobar degeneration.

Authors:  David S Knopman; Bradley F Boeve; Joseph E Parisi; Dennis W Dickson; Glenn E Smith; Robert J Ivnik; Keith A Josephs; Ronald C Petersen
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

9.  Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.

Authors:  Nobuyuki Okamura; Hiroyuki Arai; Masahiro Maruyama; Makoto Higuchi; Toshifumi Matsui; Haruko Tanji; Takashi Seki; Hisao Hirai; Hiroshi Chiba; Masatoshi Itoh; Hidetada Sasaki
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

10.  Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.

Authors:  Marta Encinas; Ramón De Juan; Alberto Marcos; Pedro Gil; Ana Barabash; Cristina Fernández; Carmen De Ugarte; José Antonio Cabranes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-15       Impact factor: 9.236

View more
  37 in total

Review 1.  Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease.

Authors:  Christina E Wierenga; Chelsea C Hays; Zvinka Z Zlatar
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity.

Authors:  Hovig Kouyoumdjian; David C Zhu; Mohammad H El-Dakdouki; Kelly Lorenz; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  ACS Chem Neurosci       Date:  2013-01-16       Impact factor: 4.418

4.  Biological heterogeneity in ADNI amnestic mild cognitive impairment.

Authors:  Jasmine Nettiksimmons; Charles DeCarli; Susan Landau; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2014-01-10       Impact factor: 21.566

5.  Increased fMRI signal with age in familial Alzheimer's disease mutation carriers.

Authors:  Meredith N Braskie; Luis D Medina; Yaneth Rodriguez-Agudelo; Daniel H Geschwind; Miguel Angel Macias-Islas; Jeffrey L Cummings; Susan Y Bookheimer; John M Ringman
Journal:  Neurobiol Aging       Date:  2010-12-03       Impact factor: 4.673

6.  Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study.

Authors:  Silvia Morbelli; Arnoldo Piccardo; Giampiero Villavecchia; Barbara Dessi; Andrea Brugnolo; Alessandra Piccini; Anna Caroli; Giovanni Frisoni; Guido Rodriguez; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

7.  Age-associated reductions in cerebral blood flow are independent from regional atrophy.

Authors:  J Jean Chen; H Diana Rosas; David H Salat
Journal:  Neuroimage       Date:  2010-12-16       Impact factor: 6.556

8.  Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings.

Authors:  Bliss Elizabeth O'Bryhim; Rajendra S Apte; Nathan Kung; Dean Coble; Gregory P Van Stavern
Journal:  JAMA Ophthalmol       Date:  2018-11-01       Impact factor: 7.389

9.  Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation.

Authors:  W Staffen; J Bergmann; U Schönauer; H Zauner; M Kronbichler; S Golaszewski; G Ladurner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-10       Impact factor: 9.236

10.  Patterns of cerebral hypoperfusion in amnestic and dysexecutive MCI.

Authors:  Linda L Chao; Judy Pa; Audrey Duarte; Norbert Schuff; Michael W Weiner; Joel H Kramer; Bruce L Miller; Katie M Freeman; Julene K Johnson
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jul-Sep       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.